MedImpact is the first pharmacy benefit manager (PBM) in the US to alert prescribers based on their genetic profile.
Pharmacogenetics (PGx) is the study of how an individual’s genetic makeup affects their drug response and metabolism. An understanding of PGx could help clinicians make prescribing decisions and has the potential to be implemented in routine care worldwide. PGx has understandably been gaining traction and support, with pharmacogenomic elements being implemented into many international Genomic studies.
Scientists at the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have found that drugs used for inflammation, diabetes, alcoholism, and arthritis also have anti-cancer properties. Published in Nature Cancer, this is the first study to screen an entire collection of mostly non-cancer drugs to see if they can kill cancer cells.
A genetic variant associated with poor response to a common asthma treatment has been identified in a new study by the Cleveland Clinic. The research team found that a particular gene variant was present in asthmatic patients who were less likely to respond to glucocorticoids and often develop severe asthma.
Genetic and genomic testing has been a hot topic in the healthcare industry in recent years. The NHS has introduced a Genomic Medicine Service (GMS) in an aim to ensure equitable access to genetic and genomic testing and integrate this into routine NHS care by 2025, driving more personalised treatments for patients in the process.
We met with Chris Wigley, CEO and Sir Mark Caulfield, Chief Scientist at Genomics England, at the first Genomics England Research conference taking place in November 2019 in London. We started by asking them how Genomics England is getting on with their objectives.
A new study by Northwestern Medicine has become the first to compare gene expression levels in African American populations by studying the levels of mRNA expressed in the liver. Previous studies have compared only African and European individuals separately and this study aimed to address the “grey” area of mixed ethnicities.
Changing Attitudes to Cannabis Cannabis is now legalised for recreational use in 11 US states and attitudes around its risk are changing rapidly. Between 2002 and 2014, the percentage of adults in the US who perceived cannabis use as risky declined from 50% to 33%. However, as cannabis usage becomes more widespread the health risks […]
D4: Pharma is a highly-select gathering of 80-100 very senior and experienced pharma professionals responsible for making important decisions, as well as turning innovation and new ideas into measurable progress.
Maize is one of the most economically important crops globally and much effort has been spent generating the high quality B73 reference genome. However, the 10 chromosome, 2.3 gigabase (Gb) B73 reference genome was a substantial challenge due to the fact it is comprised of 85% transposable elements, 75% of which are long terminal […]
Independent US Food and Drug Administration (FDA) advisors unanimously backed Celltrion’s new Rituxan biosimilar recently, potentially allowing the company to threaten the sales dominance of Roche’s top drug.
ASCO checkpoint inhibitor battle between Merck and Roche highlights the pitfalls in directly comparing clinical trial results in the era of precision medicine.
Precision medicine is showing significant signs of success across tumour types.